Resources for a Family of Diseases
  Rituxan in Churg Strauss Syndrome - Pilot Study at MayoThe Mayo Clinic Nephrology Collaborative Group (MNCG) announces a new pilot study on the use of Rituximab in the treatment of Churg Strauss Syndrome with renal involvement. The plan is to enroll five patients in the open label study using four weekly doses of Rituximab. Patients will be followed for one year after beginning of the remission induction regimen. Disease relapses, as defined in the protocol will be treated according to the standard of practice for patients with this disease. To learn more: 1813 726 Print This Email This
|
Vasculitis Foundation Research Grant ProgramMedical ConsultantsVF medical consultants provide advice by telephone or e-mail to physicians who treat patients with Vasculitis.
|
About Vasculitis Foundation
The Vasculitis Foundation (VF) is the only international organization for patients with Vasculitis. Founded in 1986, VF provides patients and family members with practical information and coping strategies to live successfully with Vasculitis.
Mission: The Vasculitis Foundation supports and empowers patients through education, awareness and research. Learn more